Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of acalabrutinib plus best supportive care versus best supportive care in hospitalized COVID-19 patients
2020-001644-25Phase 2Completed
- Sponsor
- Acerta Pharma
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in coronavirus disease 2019 (COVID-19) comparing acalabrutinib + best supportive care with best supportive care alone (2 arms). Primary endpoint: Treatment failure rate. Started Apr 2020; status: completed.
02
Drugs
acalabrutinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001644-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001644-25.